Caxton Associates LLP Invests $552,000 in Boston Scientific Corporation $BSX

Key Points

• Caxton Associates LLP acquired a new stake in Boston Scientific Corporation, purchasing 5,476 shares valued at approximately $552,000 during the first quarter.
• Boston Scientific reported a 22.8% year-over-year increase in revenue, reaching $5.06 billion, and exceeded analysts' EPS estimates of $0.72 by reporting $0.75.
• Institutional investors and hedge funds own 89.07% of Boston Scientific's stock, indicating significant institutional interest in the company.

Caxton Associates LLP acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,476 shares of the medical equipment provider's stock, valued at approximately $552,000.

A number of other hedge funds have also recently bought and sold shares of BSX. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG grew its stake in Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE grew its position in shares of Boston Scientific by 6.2% in the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after acquiring an additional 1,439 shares in the last quarter. Gotham Asset Management LLC grew its position in shares of Boston Scientific by 43.7% in the 4th quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider's stock worth $1,021,000 after acquiring an additional 3,475 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Boston Scientific by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 321,764 shares of the medical equipment provider's stock worth $28,740,000 after acquiring an additional 18,146 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insiders Place Their Bets

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares of the company's stock, valued at $222,646.19. The trade was a 58.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $18,397,457 over the last 90 days. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Boston Scientific stock traded down $1.63 during mid-day trading on Friday, hitting $102.71. 10,541,837 shares of the company's stock traded hands, compared to its average volume of 6,118,901. The firm has a 50 day moving average price of $104.86 and a 200 day moving average price of $102.26. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market cap of $152.19 billion, a PE ratio of 61.14, a price-to-earnings-growth ratio of 2.51 and a beta of 0.65. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on BSX. Needham & Company LLC reiterated a "buy" rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Thursday. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Wells Fargo & Company boosted their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Raymond James Financial boosted their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th. Finally, Leerink Partners initiated coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $118.04.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.